Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Tolerability and Safety of New or Repurposed Drugs Against Lassa Fever in West African Countries

NCT06212336 is registered in ClinicalTrials.gov with Irrua Specialist Teaching Hospital as lead sponsor.

NCT NCT06212336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06212336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Tolerability and Safety of New or Repurposed Drugs Against Lassa Fever in West African Countries
Lead sponsor
Irrua Specialist Teaching Hospital
Phase
Phase 2/3
Overall status
Recruiting
Start date
May 2, 2025
Completion date
June 30, 2027
Enrollment
1,755 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lassa fever